Country: United States
Language: English
Source: NLM (National Library of Medicine)
DICLOXACILLIN SODIUM (UNII: 4HZT2V9KX0) (DICLOXACILLIN - UNII:COF19H7WBK)
A-S Medication Solutions
DICLOXACILLIN SODIUM
DICLOXACILLIN 250 mg
ORAL
PRESCRIPTION DRUG
To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ). Dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. Dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.
Product: 50090-0116 NDC: 50090-0116-1 40 CAPSULE in a BOTTLE NDC: 50090-0116-0 28 CAPSULE in a BOTTLE NDC: 50090-0116-4 20 CAPSULE in a BOTTLE Product: 50090-0310
Abbreviated New Drug Application
DICLOXACILLIN SODIUM- DICLOXACILLIN SODIUM CAPSULE A-S MEDICATION SOLUTIONS ---------- DICLOXACILLIN SODIUM CAPSULES USP RX ONLY To reduce the development of drug resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Dicloxacillin sodium, USP is an antibacterial agent of the isoxazolyl penicillin series. It is a penicillinase resistant, acid resistant semisynthetic penicillin suitable for oral administration. It is monosodium (2_S_,5_R_,6_R_)-6-[3-(2,6-dichlorophenyl)-5-methyl-4- isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2- carboxylate monohydrate, and has following structural formula: C H Cl N NaO S·H O MW 510.32 Each capsule for oral administration contains dicloxacillin sodium, USP equivalent to 250 mg or 500 mg of dicloxacillin. The inactive ingredient is Magnesium Stearate. The capsule shells and print constituents contains D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #1, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake, D&C Yellow #10, Gelatin, Shellac, Sodium Lauryl Sulfate, Sorbitan Monolaurate, Black Iron Oxide, Titanium Dioxide, Propylene Glycol. CLINICAL PHARMACOLOGY MICROBIOLOGY _Mechanism of Action_ Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. _Antibacterial Activity_ Dicloxacillin sodium has been shown to be active against most isolates of the following microorganisms, both _in vitro_ and in clinical infections as described in the INDICATIONS 19 16 2 3 5 2 AND USAGE section. Gram-positive Bacteria _Staphylococcus_ spp. _Susceptibility Testing_ For specific information regarding susceptibility test interpretive criteria and associated test methods and Read the complete document